|
1
|
Trétarre B, Molinié F, Woronoff AS,
Bossard N, Bessaoud F, Marrer E, Grosclaude P, Guizard AV,
Delafosse P, Bara S, et al: Ovarian cancer in France: Trends in
incidence, mortality and survival, 1980–2012. Gynecol Oncol.
139:324–329. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Edwards HM, Noer MC, Sperling CD,
Nguyen-Nielsen M, Lundvall L, Christensen IJ and Høgdall C:
Survival of ovarian cancer patients in Denmark: Results from the
Danish gynaecological cancer group (DGCG) database, 1995–2012. Acta
Oncol. 55 Suppl 2:S36–S43. 2016. View Article : Google Scholar
|
|
3
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang J, Hu W and Sood AK: Prognostic
biomarkers in ovarian cancer. Cancer Biomark. 8:231–251. 2010–2011.
View Article : Google Scholar
|
|
5
|
Lu LF, Boldin MP, Chaudhry A, Lin LL,
Taganov KD, Hanada T, Yoshimura A, Baltimore D and Rudensky AY:
Function of miR-146a in controlling Treg cell-mediated regulation
of Th1 responses. Cell. 142:914–929. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Labbaye C and Testa U: The emerging role
of miR-146A in the control of hematopoiesis, immune function and
cancer. J Hematol Oncol. 5:132012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PLoS One. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge
YY, Yang JR, Su H and Zhuang SM: A functional polymorphism in the
miR-146a gene is associated with the risk for hepatocellular
carcinoma. Carcinogenesis. 29:2126–2131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kogo R, Mimori K, Tanaka F, Komune S and
Mori M: Clinical significance of miR-146a in gastric cancer cases.
Clin Cancer Res. 17:4277–4284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Williams AE, Perry MM, Moschos SA,
Larner-Svensson HM and Lindsay MA: Role of miRNA-146a in the
regulation of the innate immune response and cancer. Biochem Soc
Trans. 36:1211–1215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen J, Ambrosone CB, DiCioccio RA, Odunsi
K, Lele SB and Zhao H: A functional polymorphism in the miR-146a
gene and age of familial breast/ovarian cancer diagnosis.
Carcinogenesis. 29:1963–1966. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:pp. 19075–19080. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hurst DR, Edmonds MD, Scott GK, Benz CC,
Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1
up-regulates miR-146, which suppresses breast cancer metastasis.
Cancer Res. 69:1279–1283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boldin MP, Taganov KD, Rao DS, Yang L,
Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J,
et al: miR-146a is a significant brake on autoimmunity,
myeloproliferation, and cancer in mice. J Exp Med. 208:1189–1201.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang TC, Yu D, Lee YS, Wentzel EA, Arking
DE, West KM, Dang CV, Thomas-Tikhonenko A and Mendell JT:
Widespread microRNA repression by Myc contributes to tumorigenesis.
Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng H, Liu JY, Song FJ and Chen KX:
Advances in circulating microRNAs as diagnostic and prognostic
markers for ovarian cancer. Cancer Biol Med. 10:123–130.
2013.PubMed/NCBI
|
|
18
|
Di Leva G and Croce CM: The role of
microRNAs in the tumorigenesis of ovarian cancer. Front Oncol.
3:1532013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee H, Park CS, Deftereos G, Morihara J,
Stern JE, Hawes SE, Swisher E, Kiviat NB and Feng Q: MicroRNA
expression in ovarian carcinoma and its correlation with
clinicopathological features. World J Surg Oncol. 10:1742012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng H, Zhang L, Zhao Y, Yang D, Song F,
Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as diagnostic
and prognostic biomarkers for ovarian cancer. PLoS One.
8:e778532013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kan CWS, Hahn MA, Gard GB, Maidens J, Huh
JY, Marsh DJ and Howell VM: Elevated levels of circulating
microRNA-200 family members correlate with serous epithelial
ovarian cancer. BMC Cancer. 12:6272012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Delfino KR and Rodriguez-Zas SL:
Transcription factor-microRNA-target gene networks associated with
ovarian cancer survival and recurrence. PLoS One. 8:e586082013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Xu H, Shen H and Li H: microRNA 106a
modulates cisplatin sensitivity by targeting PDCD4 in human ovarian
cancer cells. Oncol Lett. 7:183–188. 2014.PubMed/NCBI
|
|
24
|
Mitamura T, Watari H, Wang L, Kanno H,
Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, et
al: Downregulation of miRNA-31 induces taxane resistance in ovarian
cancer cells through increase of receptor tyrosine kinase MET.
Oncogenesis. 2:e402013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vecchione A, Belletti B, Lovat F, Volini
S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC,
Pellegrini P, et al: A microRNA signature defines chemoresistance
in ovarian cancer through modulation of angiogenesis. Proc Natl
Acad Sci USA. 110:pp. 9845–9850. 2013; View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Lu Y, Chen Y, Lu W and Xie X:
MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma
based on formalin-fixed paraffin-embedded samples. BMC Cancer.
13:2162013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vang S, Wu HT, Fischer A, Miller DH,
MacLaughlan S, Douglass E, Comisar L, Steinhoff M, Collins C, Smith
PJ, et al: Identification of ovarian cancer metastatic miRNAs. PLoS
One. 8:e582262013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wyman SK, Parkin RK, Mitchell PS, Fritz
BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS and
Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as
determined by next generation sequencing of small RNA cDNA
libraries. PLoS One. 4:e53112009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cui Y, She K, Tian D, Zhang P and Xin X:
miR-146a inhibits proliferation and enhances chemosensitivity in
epithelial ovarian cancer via reduction of SOD2. Oncol Res.
23:275–282. 2016. View Article : Google Scholar
|
|
32
|
Chen Y, Zhang L and Hao Q: Candidate
microRNA biomarkers in human epithelial ovarian cancer: Systematic
review profiling studies and experimental validation. Cancer Cell
Int. 13:862013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garcia AI, Buisson M, Bertrand P, Rimokh
R, Rouleau E, Lopez BS, Lidereau R, Mikaélian I and Mazoyer S.:
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in
triple negative sporadic breast cancers. EMBO Mol Med. 3:279–290.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Diaz-Cano SJ: Tumor heterogeneity:
Mechanisms and bases for a reliable application of molecular marker
design. Int J Mol Sci. 13:1951–2011. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kobayashi M, Salomon C, Tapia J, Illanes
SE, Mitchell MD and Rice GE: Ovarian cancer cell invasiveness is
associated with discordant exosomal sequestration of Let-7 miRNA
and miR-200. J Transl Med. 12:42014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Périgny M, Bairati I, Harvey I, Beauchemin
M, Harel F, Plante M and Têtu B: Role of immunohistochemical
overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the
prognosis of death by ovarian cancer. Am J Clin Pathol.
129:226–231. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bachmayr-Heyda A, Auer K, Sukhbaatar N,
Aust S, Deycmar S, Reiner AT, Polterauer S, Dekan S and Pils D:
Small RNAs and the competing endogenous RNA network in high grade
serous ovarian cancer tumor spread. Oncotarget. 7:39640–39653.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, VandenBoom TG II, Wang Z, Kong D,
Ali S, Philip PA and Sarkar FH: MiR-146a suppresses invasion of
pancreatic cancer cells. Cancer Res. 70:1486–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ,
Soletormos G, Torre GC, Tuxen MK and Zwirner M: CA125 in ovarian
cancer: European group on tumor markers guidelines for clinical
use. Int J Gynecol Cancer. 15:679–691. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
But I and Gorisek B: Preoperative value of
CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
Gynecol Oncol. 63:166–172. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Topalak O, Saygili U, Soyturk M, Karaca N,
Batur Y, Uslu T and Erten O: Serum, pleural effusion, and ascites
CA-125 levels in ovarian cancer and nonovarian benign and malignant
diseases: A comparative study. Gynecol Oncol. 85:108–113. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rossi AC, Di Vagno G, Cormio G, Cazzolla
A, Stefanelli S, D'Elia E and Selvaggi L: A retrospective study of
preoperative CA 125 levels in 82 patients with ovarian cancer. Arch
Gynecol Obstet. 269:263–265. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ayhan A, Guven S, Guven ES and Kucukali T:
Is there a correlation between tumor marker panel and tumor size
and histopathology in well-staged patients with borderline ovarian
tumors? Acta Obstet Gynecol Scand. 86:484–490. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Markmann S, Gerber B and Briese V:
Prognostic value of Ca 125 levels during primary therapy.
Anticancer Res. 27:1837–1839. 2007.PubMed/NCBI
|
|
47
|
Mano A, Falcão A, Godinho I, Santos J,
Leitão F, Oliveira C and Caramona M: CA-125 AUC as a new prognostic
factor for patients with ovarian cancer. Gynecol Oncol. 97:529–534.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Moore RG, McMeekin DS, Brown AK,
DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC
Jr and Skates SJ: A novel multiple marker bioassay utilizing HE4
and CA125 for the prediction of ovarian cancer in patients with a
pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bandiera E, Romani C, Specchia C, Zanotti
L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F,
et al: Serum human epididymis protein 4 and risk for ovarian
malignancy algorithm as new diagnostic andprognostic tools for
epithelial ovarian cancer management. Cancer Epidemiol Biomarkers
Prev. 20:2496–2506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Steffensen KD, Waldstrøm M, Brandslund I,
Petzold M and Jakobsen A: The prognostic and predictive value of
combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol
Cancer. 22:1474–1482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y
and Chen G: miR-125b confers resistance of ovarian cancer cells to
cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J
Huazhong Univ Sci Technolog Med Sci. 31:543–549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li H, Xu H, Shen H and Li H: microRNA-106a
modulates cisplatin sensitivity by targeting PDCD4 in human ovarian
cancer cells. Oncol Lett. 7:183–188. 2014.PubMed/NCBI
|
|
53
|
Bhaumik D, Scott GK, Schokrpur S, Patil
CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses
NF-kappaB activity with reduction of metastatic potential in breast
cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rayet B and Gélinas C: Aberrant rel/nfkb
genes and activity in human cancer. Oncogene. 18:6938–6947. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pecorelli S, Ngan HYS and Hacker NF:
Staging classifications and clinical practice guidelines for
gynaecological cancersA collaboration between FIGO and IGCS. 3rd.
London: FIGO; 2006
|
